Engaging In Insider Activity, Kristin Patrick At Niagen Bioscience Exercises Options Worth $0

Disclosed in a recent SEC filing on June 26, Patrick, Board Member at Niagen Bioscience NAGE, made a noteworthy transaction involving the exercise of company stock options.

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Patrick, Board Member at Niagen Bioscience, a company in the Health Care sector, just exercised stock options worth 0 shares of NAGE stock with an exercise price of $0.0.

The latest update on Friday morning shows Niagen Bioscience shares down by 0.43%, trading at $13.76. At this price, Patrick's 0 shares are worth $0.

All You Need to Know About Niagen Bioscience

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

Key Indicators: Niagen Bioscience's Financial Health

Revenue Growth: Niagen Bioscience displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 37.59%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Key Profitability Indicators:

• Gross Margin: With a high gross margin of 63.42%, the company demonstrates effective cost control and strong profitability relative to its peers.

• Earnings per Share (EPS): Niagen Bioscience's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.07.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.06.

Valuation Metrics: A Closer Look

• Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 76.78 suggests caution, as the stock may be overvalued in the eyes of investors.

• Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 10.26 suggests overvaluation in the eyes of investors, considering sales performance.

• EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): At 70.56, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.

Exploring the Significance of Insider Trading

While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.

In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.

Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.

Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.

A Closer Look at Important Transaction Codes

When it comes to transactions, investors tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of Niagen Bioscience's Insider Trades.

Insider Buying Alert: Profit from C-Suite Moves

Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.

This article was generated by Benzinga's automated content engine and reviewed by an editor.